Matching medicines to patients
Personalised Healthcare (PHC) aims to match medicines to only those patients who will benefit from them. Advances in science mean we can increasingly design and use tests to tell us how an individual patient is likely to respond to a particular medication before prescribing it for them. Developing medicines in this way changes the way healthcare is delivered to patients. It means better, more effective treatment for patients and proven value for payers.
AZD4547 is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor currently in Phase I trials for gastric and breast cancers. An early PHC strategy let us focus our discovery and translational effort to the right disease segment, using the relevant models.
We now have robust preclinical data that will enable us to target the right patient population starting in early development. This will, in turn, enable clear decisions about the future of this exciting programme.